SVB Securities analyst Jonathan Chang reiterated a Buy rating on Vincerx Pharma Inc (VINC – Research Report) on November 10 and set a price target of $5.00. The company’s shares closed last Friday at $0.84.
Chang covers the Healthcare sector, focusing on stocks such as Bicycle Therapeutics, Adaptimmune Therapeutics, and Immatics. According to TipRanks, Chang has an average return of -11.5% and a 31.11% success rate on recommended stocks.
Vincerx Pharma Inc has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.
See the top stocks recommended by analysts >>
Based on Vincerx Pharma Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $18.42 million. In comparison, last year the company had a GAAP net loss of $2.03 million
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VINC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LifeSci Acquisition Corp is a blank check company.
Read More on VINC:
